Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19685401 | 0.93 | MAPT (0.44) | MAPTLMNAMEN1HTTKMT2A | |
| SCHEMBL19916692 | 0.92 | MAPT (0.56) | MAPTLMNAMEN1HTTKMT2A | |
| SCHEMBL19132310 | 0.88 | MAPT (0.54) | MAPTLMNAMEN1HTTKMT2A | |
| SCHEMBL19132607 | 0.85 | MAPT (0.61) | MAPTLMNAMEN1HTTKMT2A | |
| SCHEMBL19916727 | 0.84 | MAPT (0.46) | MAPTLMNAMEN1HTTKMT2A | |
| SCHEMBL15424153 | 0.83 | MAPT (0.59) | MAPTLMNAMEN1HTTKMT2A | |
| SCHEMBL12480937 | 0.81 | MAPT (0.56) | MAPTLMNAMEN1HTTKMT2A | |
| SCHEMBL15424141 | 0.81 | MAPT (0.60) | MAPTLMNAMEN1HTTKMT2A | |
| SCHEMBL12481925 | 0.81 | MAPT (0.65) | MAPTLMNAMEN1HTTKMT2A | |
| SCHEMBL12481161 | 0.79 | MAPT (0.54) | MAPTLMNAMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349573-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS INC (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349573-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GLI1, SHH, HDAC1 | MAPT 3245/4885LMNA 4754/4885MEN1 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.